VERU INC. reported six months ended March 31, 2026 results: net income $8.1 million, or $0.37 per share, EPS $0.37 per share.
“Net loss decreased to $8.1 million, or $0.37 per share, compared to $16.8 million, or $1.15 per share”
VERU INC. — fact timeline
Source-grounded facts extracted from VERU INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VERU INC. reported fiscal 2026 second quarter ended March 31, 2026 results: net income $2.7 million, or $0.12 per share, EPS $0.12 per share.
“Net loss decreased to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share”
VERU INC.: Articles of Amendment filed to effect a 1-for-10 reverse stock split of the common stock, effective 11:59 pm CT on August 8, 2025 (effective 2025-08-08).
“On August 8, 2025, Veru Inc. (the "Company") filed Articles of Amendment to the Company's Amended and Restated Articles of Incorporation to effect a 1-for-10 reverse stock split (the "Reverse Stock Split") of the Company's issued and outstanding shares of common stock, par value $0.01 per share (the "Common Stock"), effective 11:59 pm CT on August 8, 2025 (the “Effective Time”).”
VERU INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 27, 2025, the Company received a notification (the “Extension Notice”) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until August 25, 2025, to regain compliance with the minimum closing bid price requirement under the Rule for continued listing on Nasdaq. The Extension Notice has no immediate effect on the listing of the Company’s common stock. In connection with its request for an extension, the Company stated that it intends to cure its bid price deficiency during such additional 180-day period, by effecting a reverse stock”
VERU INC. completed a disposition involving Clear Future, Inc. for $18.0 million in cash, subject to customary working capital adjustment (closed 2024-12-30).
“relating to the FC2 business that are specified in the Purchase Agreement. The transaction closed on December 30, 2024. The purchase price for the FC2 Business Sale is $18.0 million in cash, subject to adjustment as set forth in the Purchase Agreement. The adjustments to the purchase price in the Purchase Agreement include a customary working capital”
Loren Mark Katzovitz was appointed as Director at VERU INC..
“appointed Loren Mark Katzovitz to fill the vacancy created thereby.”
VERU INC. reported the quarter and six months ended March 31, 2024 results: revenue $4.1 million, net income $10.0 million, or $0.07 per share, EPS $0.07 per share.
“the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025. Second Quarter Financial Summary: Fiscal 2024 vs Fiscal 2023 • Net revenues decreased to $4.1 million from $6.6 million • Gross profit decreased to $0.7 million from $4.1 million • Research and development expenses decreased to $3.0 million from $17.9 million, as restated •”
VERU INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“February 21, 2024, Veru Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission, the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Notice has no immediate effect on the listing or trading of the Company’s common stoc”
VERU INC. reported that prior financial statements should not be relied upon.
“On February 15, 2024, the Audit Committee of the Board of Directors of Veru Inc. (the “Company”), based on the recommendation of management, concluded that the Company’s previously issued consolidated financial statements as of and for the year ended September 30, 2023 (the “Prior Financial Statements”) should no longer be relied upon due to errors”
VERU INC. reported financial results for fiscal 2024 first quarter ended December 31, 2023.
“On February 8, 2024, Veru Inc. issued a press release (the “Press Release”) announcing certain financial highlights for the quarter ended December 31, 2023.”
VERU INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 25, 2024, Veru Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A”
VERU INC. entered into Underwriting Agreement with Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. valued at Offering of 45,833,333 shares of common stock at $0.72 per share, net proceeds approximately $35.2 m (effective 2023-12-14).
“On December 14, 2023, Veru Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Raymond James & Associates, Inc. and Oppenheimer & Co. Inc., as representatives of the underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale (the “Offering”) of 45,833,333 shares of the Company’s common stock, par value $0.01 per share, at a public offering price of $0.72 per share.”
VERU INC. amended the Amendment with Lincoln Park Capital Fund, LLC valued at from $100 million to $50 million (effective 2023-12-13).
“On December 13, 2023, the Company entered into an amendment (the “Amendment”) to the Agreements to reduce the amount of shares of common stock subject to the registration under the Agreements from $100 million to $50 million until the Company has sold at least $50 million of shares of common stock under the Purchase Agreement.”
VERU INC. reported that prior financial statements should not be relied upon.
“On November 10, 2023, in connection with the preparation of consolidated financial statements for the year ended September 30, 2023, Veru Inc. (the “Company”) concluded that its previously issued unaudited condensed consolidated financial statements as of and for the three and nine months ended June 30, 2023 (the “Prior Financial Statements”) should no longer be relied upon due to the identification of an error related to the accounting for the sale of ENTADFI assets on April 19, 2023”
VERU INC. amended Amendment with Blue Water Biotech Inc. f/k/a Blue Water Vaccines Inc. (the Purchaser) valued at $1,000,000 (effective 2023-09-29).
“On September 29, 2023, Veru Inc. (the “Company”) entered into an Amendment to Asset Purchase Agreement (the “Amendment “) with Blue Water Biotech Inc. f/k/a Blue Water Vaccines Inc. (the “Purchaser”).”
VERU INC. reported financial results for the quarter and nine months ended June 30, 2023.
“On August 10, 2023, Veru Inc. issued a press release (the “Press Release”) announcing results for the quarter and nine months ended June 30, 2023.”
VERU INC.: Increased authorized shares of common stock from 154,000,000 to 308,000,000 (effective 2023-07-24).
“On July 24, 2023, Veru Inc. (the “Company”) filed the Articles of Amendment with the Wisconsin Department of Financial Institutions. The Articles of Amendment increase the total number of authorized shares of the Company’s common stock from 154,000,000 to 308,000,000.”
VERU INC. shareholders approved Adjournment of the Special Meeting at the 2023-07-24 meeting.
“2. Adjournment Proposal: The shareholders voted in favor of approving the adjournment of the Special Meeting. Votes For Votes Against Abstentions Broker Non-Votes 61,372,471 4,391,943 412,370 0”
VERU INC. shareholders approved Amendment to the Company's Articles of Incorporation to increase the number of authorized shares of common stock from 154,000,000 to 308,000,000 at the 2023-07-24 meeting.
“1. Share Increase Proposal: The shareholders voted to approve an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock of the Company from 154,000,000 to 308,000,000. Votes For Votes Against Abstentions Broker Non-Votes 62,042,114 3,935,354 199,316 0”
VERU INC. entered into Sales Agreement with Jefferies LLC valued at $75 million (effective 2023-05-12).
“On May 12, 2023, the Company entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), as sales agent, pursuant to which we may issue and sell, from time to time, through Jefferies, shares of our common stock, par value $0.01 per share (the “Common Stock”), with an aggregate value of up to $75 million”
VERU INC. reported financial results for the quarter and six months ended March 31, 2023.
“On May 11, 2023, Veru Inc. issued a press release (the "Press Release") announcing results for the quarter and six months ended March 31, 2023.”
VERU INC. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $100,000,000 (effective 2023-05-02).
“On May 2, 2023, Veru Inc. (the “Company”), entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park” or “Investor”) (each, a “Party”, and together, the “Parties”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may sell to Lincoln Park up to $100,000,000 of shares (the “Purchase Shares”) of the Company’s common stock”
VERU INC. completed a disposition involving Blue Water Vaccines Inc. for $20.0 million (closed 2023-04-19).
“purchased substantially all of the assets related to the Company’s ENTADFI ® business. The transaction closed on April 19, 2023. The purchase price for the transaction was $20.0 million, consisting of $6.0 million paid at closing, an additional $4.0 million the Purchaser is obligated to pay the Company in the Company’s fiscal year 2023 and an additional $10”
VERU INC. entered into Asset Purchase Agreement with Blue Water Vaccines Inc. valued at $20.0 million purchase price: $6.0 million closing, $4.0 million fiscal 2023, $10 million fiscal 202 (effective 2023-04-19).
“On April 19, 2023, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Blue Water Vaccines Inc. (the “Purchaser”).”
VERU INC. entered into Purchase Agreement with Frost Gamma Investments Trust valued at $5,000,000 (effective 2023-04-12).
“On April 12, 2023, Veru Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Frost Gamma Investments Trust (the “Purchaser”), pursuant to which, on the date thereof, the Company issued and sold 5,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), to the Purchaser at a purchase price of $1.00 per share, for a total investment of $5,000,000.”
VERU INC. shareholders approved Advisory (non-binding) vote on the frequency of the advisory vote on the executive compensation of the Company’s named executive officers at the 2023-03-28 meeting.
“4. Advisory (non-binding) vote on the frequency of the advisory vote on the executive compensation of the Company’s named executive officers: The shareholders voted to recommend that the Company include an advisory vote on the compensation of the Company’s named executive officers pursuant to the rules of the Securities and Exchange Commission every three years.”
VERU INC. shareholders approved Advisory (non-binding) vote on the executive compensation of the Company’s named executive officers at the 2023-03-28 meeting.
“3. Advisory (non-binding) vote on the executive compensation of the Company’s named executive officers: The shareholders voted in favor of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting.”
VERU INC. shareholders approved Ratification of Auditors at the 2023-03-28 meeting.
“2. Ratification of Auditors: The shareholders voted to ratify the appointment by the Company’s Audit Committee of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.”
VERU INC. shareholders approved Election of Directors at the 2023-03-28 meeting.
“1. Election of Directors: The following individuals were nominated for election to the Board of Directors for terms that expire at the next annual meeting of shareholders. All of the nominated directors were elected.”
VERU INC. reported fiscal 2023 first quarter results: revenue $2.5 million, net income $36.8 million, or $0.46 per share.
“with an enlarged prostate experiencing the signs and symptoms of BPH for up to 26 weeks. First Quarter Financial Summary: Fiscal 2023 vs Fiscal 2022 • Net revenues decreased to $2.5 million from $14.1 million • Gross profit decreased to $0.7 million from $11.8 million 2 • Research and development expenses increased to $18.7 million from $10.1 million • Selling,”
VERU INC. reported financial results for fiscal 2022 fourth quarter and full year ended September 30, 2022.
“Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full year ended September 30, 2022 and provided a business update.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.